Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R34MH078925 | U.S. NIH Grant/Contract | View source | |
| DATR A4-GPS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Mental Health (NIMH) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the effectiveness of cognitive behavioral therapy in treating anxiety in older adults with dementia.
Dementia is an illness that causes memory problems; changes in behavior; and difficulty with thinking, making decisions, and carrying out daily activities. Many people with dementia also have anxiety, and yet very little is known about effective treatment strategies for anxiety in this population. Cognitive behavioral therapy (CBT) is a type of psychotherapy that is commonly used to treat anxiety. CBT involves teaching patients skills to help them manage their anxiety, such as relaxation, changing their thoughts, and problem-solving. This study will evaluate the effectiveness of CBT in treating anxiety in older adults with dementia. In addition, the study will determine the effect of the treatment on patients' families and friends, and how families and friends may be able to help patients manage their anxiety. All study participants will name a family member or friend who will also participate in the study.
All participants in this study will answer a preliminary set of questions about anxiety and memory and will then complete a number of activities that involve learning and memory. These evaluations will take approximately 45 minutes. Participants who are selected to continue in the study will answer a second set of questions about mood, memory, concentration, and how they are doing in certain areas of life. These interview questions will take place during 2 sessions and will last a total of approximately 3 hours. Participants will then be randomly assigned to receive either enhanced usual care (EUC) or 8 to 10 sessions of CBT over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day. EUC will consist of regular ongoing care from healthcare providers and phone assessments at 1-month and 2-month. Following the 6 month assessment, participants in EUC will be offered a Cognitive Behavior Workshop. Following in-person meetings, CBT participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months. Some of the pretreatment questions will be asked again at 3 months and again 6 months after baseline.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CBT-AD | Experimental | Participants will receive Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD) |
|
| EUC | Active Comparator | EUC will consist of regular ongoing care from healthcare providers and phone assessments at 1-month and 2-month. Following the 6 month assessment, participants in EUC will be offered a half-day Cognitive Behavior Workshop. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD) | Behavioral | Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day. |
| Measure | Description | Time Frame |
|---|---|---|
| Rating Anxiety in Dementia (RAID) and Neuropsychiatric Inventory (NPI)- Anxiety subscales | Measured at pre-treatment, post-treatment, and 3-month follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life in Alzheimer's Disease (QOL-AD) | Measured at pre-treatment, post-treatment, and 3-month follow-up | |
| Geriatric Depression Scale (GDS) | Measured at pre-treatment, post-treatment, and 3-month follow-up |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Melinda A. Stanley, PhD | Baylor College of Medicine | Principal Investigator |
| Jessica Calleo, PhD | Baylor College of Medicine | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Baylor College of Medicine | Houston | Texas | 77030 | United States | ||
| Michael E. DeBakey Veterans Affairs Medical Center |
Not provided
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D003704 | Dementia |
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Enhanced Usual Care (EUC) | Behavioral | Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months. |
|
| Penn State Worry Questionnaire (PSWQ) | Measured at pre-treatment, post-treatment, and 3-month follow-up |
| Geriatric Anxiety Inventory (GAI) | Measured at pre-treatment, post-treatment, and 3-month follow-up |
| Houston |
| Texas |
| 77030 |
| United States |
| D019965 | Neurocognitive Disorders |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |